{
    "nctId": "NCT05584163",
    "briefTitle": "Pilot Study to Evaluate the Prevention and Safety of Doxorubicin-induced Cardiomyopathy Using Extracorporeal Shock Waves",
    "officialTitle": "Single-center, Randomized, Prospective Controlled Pilot Study to Evaluate the Prevention and Safety of Doxorubicin-induced Cardiomyopathy Using Extracorporeal Shock Waves in Breast Cancer Patients Using Doxorubicin Anticancer Drugs",
    "overallStatus": "RECRUITING",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "NA",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "PREVENTION",
    "enrollmentCount": 72,
    "primaryOutcomeMeasure": "Chemotherapy induced cardiomyopathy",
    "eligibilityCriteria": "Inclusion Criteria:\n\n1. Breast cancer patients receiving doxorubicin chemotherapy (for patients with operable breast cancer who receive doxorubicin with neoadjuvant or adjuvant chemotherapy)\n2. Patients who are expected to receive at least 3 cycles of doxorubicin chemotherapy after registration and who can receive at least 2 extracorporeal shock wave therapy\n3. Those with a left ventricular ejection fraction of 50% or more at screening\n\nExclusion Criteria:\n\n1. Subjects under the age of 19\n2. Those who have implanted an intracardiac device (implantable defibrillator, pacemaker)\n3. Hemodynamically unstable ventricular tachycardia confirmed\n4. If you have QT prolongation syndrome or are receiving medication that increases QT interval\n\n   * Antiarrhythmics class IA; quinidine, procainamide\n   * Antiarrhythmics class III; amiodarone, sotalol\n5. Patients with atrial fibrillation or those who have undergone defibrillation for atrial fibrillation within the last 3 months\n6. In case of structural heart disease (congenital heart disease, valvular disease, etc.) and related surgery\n7. Persons who have had coronary artery disease or a subsequent PCI or coronary artery bypass surgery\n8. Those with symptoms of unstable angina requiring hospitalization\n9. Persons suspected or diagnosed with cardiomyopathy due to causes other than chemotherapy\n10. When life expectancy is less than 6 months\n11. Pregnant women or those planning to become pregnant\n12. Moderate or severe hepatic impairment (ex. Child-Pugh class B,C)\n13. Creatinine clearance \\< 30mL/min\n14. Patients judged to be inappropriate by other researchers",
    "sex": "FEMALE",
    "minimumAge": "19 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}